| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,515 |
3,304 |
$245K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,905 |
3,587 |
$209K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,063 |
2,059 |
$185K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,418 |
2,412 |
$154K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,703 |
2,399 |
$72K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
503 |
480 |
$17K |
| 99000 |
|
3,730 |
3,382 |
$15K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,038 |
557 |
$13K |
| 87428 |
|
567 |
549 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
612 |
596 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
72 |
70 |
$5K |
| 99058 |
|
50 |
47 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
89 |
84 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
199 |
194 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
50 |
48 |
$1K |
| 81002 |
|
350 |
345 |
$819.78 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
12 |
12 |
$302.28 |
| 81025 |
|
12 |
12 |
$64.17 |
| 99051 |
|
13 |
13 |
$0.00 |